{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T09:20:45Z","timestamp":1783761645688,"version":"3.55.0"},"reference-count":23,"publisher":"BMJ","issue":"11","license":[{"start":{"date-parts":[[2025,11,9]],"date-time":"2025-11-09T00:00:00Z","timestamp":1762646400000},"content-version":"unspecified","delay-in-days":8,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Boehringer Ingelheim International GmbH","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2025,10,15]]},"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Post-traumatic stress disorder (PTSD) is a heterogeneous psychiatric disorder, with symptom variation between patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>We describe clinical and demographic characteristics of patients with PTSD based on real-world data.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This non-interventional, retrospective cohort study analysed de-identified electronic health records of patients from the Holmusk NeuroBlu database in the USA. Patients with \u22652\u2009PTSD diagnoses captured in the database within 30 days between 2001 and 2020 were included. The index date was defined as the date of the first recorded PTSD diagnosis. In patients who were aged \u226518 years, demographic and clinical characteristics at baseline (index date \u00b114 days), in the 6 months prior to baseline and 12 months after baseline were described. Patients were stratified into four mutually exclusive subgroups according to treatment received: psychotherapy only, pharmacotherapy only, psychotherapy and pharmacotherapy, and untreated. Natural language processing models were used to derive PTSD symptoms from unstructured clinician-documented mental state examination data. Data were analysed descriptively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Findings<\/jats:title>\n                    <jats:p>A total of 37,449 patients had \u22652\u2009PTSD diagnoses within 30 days between 2001 and 2020; 32,875 patients received care at clinical sites with both inpatient\/outpatient units; 25,507 patients received psychotherapy and\/or pharmacotherapy as per further prespecified criteria, and 17,234 were \u226518 years old and included in this analysis. Most patients (84.9%) received psychotherapy, pharmacotherapy or both during the first year post-baseline. Mean age (SD) was 37.7 (12.4) years, 73.4% of patients were female and 59.6% were White. At baseline, 98% of patients had \u22651 psychiatric comorbidity; major depressive disorder (42.2%), substance use disorder (35%) and anxiety disorder (30.7%) were most frequently reported. Reported suicidal ideation\/attempts were most frequent in the pharmacotherapy only group compared with other subgroups at baseline. The most frequently prescribed drug classes were antidepressants (51.8%), second-generation antipsychotics (29.9%) and anxiolytics (23.3%) at baseline. Trazodone, clonazepam, quetiapine and sertraline were the most frequently prescribed medications.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In the overall study population, most patients were female, with a high prevalence of psychiatric comorbidities. Demographic and clinical characteristics observed in this study varied across treatment subgroups. These insights may support patient-specific treatment planning and inform health-economic decision models in PTSD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2025-099711","type":"journal-article","created":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T05:45:23Z","timestamp":1762753523000},"page":"e099711","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["Examining differences in clinical and demographic characteristics of patients with post-traumatic stress disorder across adult treatment subgroups based on the NeuroBlu database: a non-interventional, retrospective cohort study"],"prefix":"10.1136","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-1872-4274","authenticated-orcid":false,"given":"Staci","family":"Abramsky","sequence":"first","affiliation":[{"name":"Boehringer Ingelheim Pharmaceuticals Inc, Ridgefield, Connecticut, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne","family":"St.Rose","sequence":"additional","affiliation":[{"name":"Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi Wen","family":"Heng","sequence":"additional","affiliation":[{"name":"Holmusk Technologies, Inc, Singapore & New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L. Alexander","family":"Vance","sequence":"additional","affiliation":[{"name":"Holmusk Technologies, Inc, Singapore & New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2472-9544","authenticated-orcid":false,"given":"Ling","family":"Zhang","sequence":"additional","affiliation":[{"name":"Boehringer Ingelheim Pharmaceuticals Inc, Ridgefield, Connecticut, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly MY","family":"Chan","sequence":"additional","affiliation":[{"name":"Holmusk Technologies, Inc, Singapore & New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua G","family":"Wong","sequence":"additional","affiliation":[{"name":"Holmusk Technologies, Inc, Singapore & New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sherwin","family":"Kuah","sequence":"additional","affiliation":[{"name":"Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany"},{"name":"Holmusk Technologies, Inc, Singapore & New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li Tong","family":"Low","sequence":"additional","affiliation":[{"name":"Holmusk Technologies, Inc, Singapore & New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irina","family":"Adamczyk","sequence":"additional","affiliation":[{"name":"Boehringer Ingelheim, Baden-W\u00fcrttemberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,11,9]]},"reference":[{"key":"2025120413262326000_15.11.e099711.1","unstructured":"APA . Diagnostic and Statistical Manual of Mental Disorders Text Revision. 5th edn. American Psychiatric Association, APA, 2022."},{"key":"2025120413262326000_15.11.e099711.2","unstructured":"US Department of Veterans Affairs: PTSD: National Center for PTSD; How common is PTSD. Available: https:\/\/www.ptsd.va.gov\/ [Accessed 11 Jun 2025]."},{"key":"2025120413262326000_15.11.e099711.3","doi-asserted-by":"publisher","DOI":"10.1177\/1745691613504115"},{"key":"2025120413262326000_15.11.e099711.4","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.jpsychires.2021.01.049","article-title":"Retrospectively assessed trajectories of PTSD symptoms and their subsequent comorbidities","volume":"136","author":"Xu","year":"2021","journal-title":"J Psychiatr Res"},{"key":"2025120413262326000_15.11.e099711.5","doi-asserted-by":"publisher","DOI":"10.1007\/s10880-016-9449-8"},{"key":"2025120413262326000_15.11.e099711.6","doi-asserted-by":"crossref","unstructured":"Forman-Hoffman V , Middleton JC , Feltner C , et al . Psychological and pharmacological treatments for adults with posttraumatic stress disorder: a systematic review update. Rockville (MD); 2018.","DOI":"10.23970\/AHRQEPCCER207"},{"key":"2025120413262326000_15.11.e099711.7","unstructured":"Clinical practice guideline for the treatment of posttraumatic stress disorder (PTSD) in adults. APA. American Psychiatric Association; 2025."},{"key":"2025120413262326000_15.11.e099711.8","doi-asserted-by":"crossref","first-page":"315","DOI":"10.12740\/PP\/OnlineFirst\/157105","article-title":"A review of selected psychotherapies for PTSD, their efficacy and treatment guidelines in adults","volume":"58","author":"Kowalski","year":"2024","journal-title":"Psychiatr Pol"},{"key":"2025120413262326000_15.11.e099711.9","unstructured":"GlaxoSmithKline . Paxil (paroxetine hydrochloride) prescribing information. Available: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2008\/020031s060,020936s037,020710s024lbl.pdf [Accessed 8 Mar 2024]."},{"key":"2025120413262326000_15.11.e099711.10","unstructured":"Pfizer . Zoloft (sertraline hydrochloride). Available: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/019839s108,20990s062lbl.pdf [Accessed 8 Mar 2024]."},{"key":"2025120413262326000_15.11.e099711.11","doi-asserted-by":"crossref","unstructured":"Stanicic F , Zah V , Grbic D , et al . Treatment patterns and characteristics of patients with Post-Traumatic Stress Disorder (PTSD): a retrospective claims analysis among commercially insured population. PLoS ONE 2024;19. doi:10.1371\/journal.pone.0309704","DOI":"10.1371\/journal.pone.0309704"},{"key":"2025120413262326000_15.11.e099711.12","doi-asserted-by":"crossref","unstructured":"Schaug JP , M\u00f8ller L , Reinholt N , et al . Psychotherapies for adults with complex presentations of PTSD: a clinical guideline and five systematic reviews with meta-analyses. BMJ Ment Health 2025;28. doi:10.1136\/bmjment-2024-301158","DOI":"10.1136\/bmjment-2024-301158"},{"key":"2025120413262326000_15.11.e099711.13","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.jpsychires.2021.07.004","article-title":"Treatment response trajectories in a three-week CPT-Based intensive treatment for veterans with PTSD","volume":"141","author":"Held","year":"2021","journal-title":"J Psychiatr Res"},{"key":"2025120413262326000_15.11.e099711.14","doi-asserted-by":"publisher","DOI":"10.1002\/jts.21848"},{"key":"2025120413262326000_15.11.e099711.15","doi-asserted-by":"crossref","unstructured":"Patel R , Wee SN , Ramaswamy R , et al . NeuroBlu, an electronic health record (EHR) trusted research environment (TRE) to support mental healthcare analytics with real-world data. BMJ Open 2022;12. doi:10.1136\/bmjopen-2021-057227","DOI":"10.1136\/bmjopen-2021-057227"},{"key":"2025120413262326000_15.11.e099711.16","first-page":"28","article-title":"The clinical global impressions scale: applying a research tool in clinical practice","volume":"4","author":"Busner","year":"2007","journal-title":"Psychiatry (Edgmont)"},{"key":"2025120413262326000_15.11.e099711.17","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1162\/cpsy_a_00030","article-title":"Natural language processing-based quantication of the mental state of psychiatric patients","volume":"4","author":"Mukherjee","year":"2020","journal-title":"Computational Psychiatry"},{"key":"2025120413262326000_15.11.e099711.18","doi-asserted-by":"crossref","unstructured":"Davis LL , Schein J , Cloutier M , et al . The economic burden of posttraumatic stress disorder in the united states from a societal perspective. J Clin Psychiatry 2022;83. doi:10.4088\/JCP.21m14116","DOI":"10.4088\/JCP.21m14116"},{"key":"2025120413262326000_15.11.e099711.19","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1007\/s11414-011-9263-x","article-title":"Discrepancy in diagnosis and treatment of post-traumatic stress disorder (PTSD): treatment for the wrong reason","volume":"39","author":"Meltzer","year":"2012","journal-title":"J Behav Health Serv Res"},{"key":"2025120413262326000_15.11.e099711.20","doi-asserted-by":"publisher","DOI":"10.1037\/0033-2909.129.1.52"},{"key":"2025120413262326000_15.11.e099711.21","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1037\/adb0000205","article-title":"Relations among social support, PTSD symptoms, and substance use in veterans","volume":"30","author":"Gros","year":"2016","journal-title":"Psychol Addict Behav"},{"key":"2025120413262326000_15.11.e099711.22","doi-asserted-by":"crossref","unstructured":"Gagnon-Sanschagrin P , Schein J , Urganus A , et al . Identifying individuals with undiagnosed post-traumatic stress disorder in a large United States civilian population - a machine learning approach. BMC Psychiatry 2022;22. doi:10.1186\/s12888-022-04267-6","DOI":"10.1186\/s12888-022-04267-6"},{"key":"2025120413262326000_15.11.e099711.23","doi-asserted-by":"crossref","unstructured":"Williams T , Phillips NJ , Stein DJ , et al . Pharmacotherapy for post traumatic stress disorder (PTSD). Cochrane Database Syst Rev 2022;3. doi:10.1002\/14651858.CD002795.pub3","DOI":"10.1002\/14651858.CD002795.pub3"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2025-099711","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T21:27:31Z","timestamp":1764883651000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2025-099711"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":23,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,11,9]]},"published-print":{"date-parts":[[2025,11]]}},"alternative-id":["10.1136\/bmjopen-2025-099711"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2025-099711","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11]]}}}